1. Home
  2. LRE vs PMVP Comparison

LRE vs PMVP Comparison

Compare LRE & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lead Real Estate Co. Ltd

LRE

Lead Real Estate Co. Ltd

N/A

Current Price

$1.35

Market Cap

17.2M

Sector

N/A

ML Signal

N/A

Logo PMV Pharmaceuticals Inc.

PMVP

PMV Pharmaceuticals Inc.

HOLD

Current Price

$1.46

Market Cap

79.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LRE
PMVP
Founded
2001
2013
Country
Japan
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.2M
79.5M
IPO Year
2022
2020

Fundamental Metrics

Financial Performance
Metric
LRE
PMVP
Price
$1.35
$1.46
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$5.00
AVG Volume (30 Days)
23.9K
839.1K
Earning Date
07-30-2015
03-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$3.16
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.00
$0.82
52 Week High
$2.86
$1.88

Technical Indicators

Market Signals
Indicator
LRE
PMVP
Relative Strength Index (RSI) 48.24 52.99
Support Level $1.34 $1.32
Resistance Level $1.43 $1.48
Average True Range (ATR) 0.09 0.09
MACD 0.00 -0.02
Stochastic Oscillator 16.84 1.36

Price Performance

Historical Comparison
LRE
PMVP

About LRE Lead Real Estate Co. Ltd

Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa Prefecture, and Sapporo. The company also operates hotels in Tokyo and leases apartment units to individual customers in Japan and Dallas, Texas. Its revenue is predominantly generated from developing and selling single-family homes and condominiums, hotel operations, and residential leasing. The company's sole operating segment is real estate sales. Geographically, it derives revenue from Japan.

About PMVP PMV Pharmaceuticals Inc.

PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.

Share on Social Networks: